Published • loading... • Updated
UK begins trials of Ebola vaccine developed in just eight weeks
The early-stage trial will test safety and immune response in 50 healthy adults as researchers race to address an outbreak in Congo and Uganda.
- On Monday, the University of Oxford launched the first human trial of a vaccine against Bundibugyo ebolavirus, seeking to combat the outbreak spreading in the Democratic Republic of Congo and Uganda.
- The Bundibugyo species has caused two previous outbreaks and currently spreads through Congo, where confirmed cases rose to 1,926, including 702 deaths, the country's public health institute said on Monday.
- Scientists at the Oxford Vaccine Group and Pandemic Sciences Institute developed the shot using the same viral vector platform as the AstraZeneca Covid vaccine; the Serum Institute of India stockpiled around 620,000 doses.
- The early-stage trial, known as BD-Ebov, will evaluate safety and immune response in 50 healthy adults aged 18 to 55, with The Coalition for Epidemic Preparedness Innovations investing up to $8.6 million.
- Chief investigator Dr. Katrina Pollock noted that Ebola species are "sisters rather than twins," requiring distinct vaccines; researchers plan further clinical studies in Uganda with year-long volunteer monitoring.
Insights by Ground AI
30 Articles
30 Articles
Oxford Ebola Vaccine: What to Know About the New Shot Entering Human Trials
Oxford has launched the first human trial of a vaccine targeting the Bundibugyo strain of Ebola, as the death toll in the Democratic Republic of Congo's outbreak passes 700 with no existing vaccine for this species of the virus.
·Singapore
Read Full Article
The Oxford Vaccine Group of the University of Oxford in England began the first Phase I clinical trial of a Bundibugyo (BDBV) Ebola vaccine in response to the ongoing outbreak in the Democratic Republic of the Congo (DRC) and neighbouring country, Uganda. The ChAdOx1 BDBV vaccine was developed by scientists from the Oxford Vaccine Group and the Pandemic Sciences Institute of the University of Oxford. It uses the same viral vector platform of the…
·Brazil
Read Full ArticleCoverage Details
Total News Sources30
Leaning Left7Leaning Right4Center6Last UpdatedBias Distribution41% Left
Bias Distribution
- 41% of the sources lean Left
41% Left
L 41%
C 35%
R 24%
Factuality
To view factuality data please Upgrade to Premium
